246pa Meta-analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-blocking Anti-erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers.

Abstract

G. Macbeath1, B. Adiwijaya1, J. Liu2, L.V. Sequist3, E. Pujade-Lauraine5, M. Higgins3, I. Tabah-Fisch5, J. Pearlberg6, V. Moyo7, W. Kubasek1, R. Nering8, A. Czibere8 Translational Research and Discovery, Merrimack Pharmaceuticals, Cambridge, MA, USA Gynecologic Oncology Program, Dana Farber Cancer Institute, Boston, MA, USA Hematology/oncology, Massachusetts General Hospital, Boston, MA, USA CHU Paris Centre Hôpital Hôtel-dieu, CHU Paris Centre Hôpital Hôtel-Dieu, Paris, FRANCE Sanofi Oncology, Sanofi, Paris, FRANCE Sanofi Oncology, Sanofi, Cambridge, MA, USA Discovery, Merrimack Pharmaceuticals, Cambridge, MA, USA Clinical Development, Merrimack Pharmaceuticals, Cambridge, MA, USA

DOI: 10.1093/annonc/mdu326.79
0204060201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Macbeath2014246paMO, title={246pa Meta-analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-blocking Anti-erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers.}, author={Gavin Macbeath and Bambang S. Adiwijaya and J Liu and Lecia V Sequist and {\'E}ric Pujade-Lauraine and M Higgins and Isabelle Tabah-Fisch and Joseph Pearlberg and Victor M. Moyo and William Kubasek and Rachel Nering and Akos G Czibere}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2014}, volume={25 suppl_4}, pages={iv82} }